ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Dr. Susan Panullo on Optune Versus Salvage Chemotherapy in Glioblastoma

Susan Panullo, MD
Published Online:10:01 PM, Thu January 28, 2016


Susan Panullo, MD, director, Neuro-oncology, director, Neurosurgical Radiosurgery, Weill Cornell Brain and Spine Center, discusses the improvement in quality of life in patients with glioblastoma treated with Optune (NovoTTF-100A). Panullo says patients treated with Optune versus patients treated with salvage chemotherapy both lived the same amount of time, with the former's quality of life being much better than the latter's.

Most recently, Optune in combination with adjuvant temozolomide received FDA approval as a treatment for patients with newly diagnosed glioblastoma multiforme (GBM) following surgery, chemotherapy, and radiation therapy.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.